patent.fyi
Applications  /  US 2026/0355140
United States Patent Application Publication

US 2026/0355140 A1

Published
Nov 12, 2026
Filed
Jul 18, 2025
Earliest date on the face
Nov 14, 2018
Classification
A61K 31/201
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

No entries.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Combination testing in veterinary tumor cultures

Primary canine osteosarcoma cells grow as three-dimensional spheroids in low-attachment plates. A nitroalkene fatty acid and carboplatin are added to the same wells, with separate wells for each single agent and the vehicle control. Fluorescence microscopy measures nuclear RAD51 foci in proliferating cells, and an ATP assay measures spheroid viability.

Component substitution

Etoposide as the DNA damaging partner

Etoposide replaces a platinum agent as the anti-neoplastic partner for a nitroalkene fatty acid. The two compounds are added together to dividing tumor cells in a multiwell plate. Etoposide stabilizes topoisomerase II cleavage complexes, and immunofluorescence measures RAD51 foci and phosphorylated histone H2AX in the treated cells.

Parameter or scale variation

Timed exposure in paired cell cultures

Matched tumor cell cultures receive the same concentrations of a nitroalkene fatty acid and cisplatin under two schedules. One arm starts both agents together, and the other starts the fatty acid 4 hours before cisplatin. Both agents remain present for 24 hours after cisplatin addition, after which matched plates are fixed for RAD51 imaging or washed for a 7-day colony formation assay.

Combination exposure across two spheroid sizes

Low-attachment microwells generate tumor spheroids with target diameters of 150 and 400 micrometers by varying the number of cells seeded per well. Both size groups receive the same concentrations of a nitroalkene fatty acid and cisplatin for 24 hours, with matched single-agent and vehicle controls. Sections through the spheroid centers are stained for RAD51 and a proliferation marker, and focus counts are tabulated by distance from the spheroid surface.

Combination with existing systems

Dual agent delivery in perfused chips

A microfluidic perfusion chip holds tumor spheroids in chambers connected to a common inlet channel. Two syringe pumps feed medium containing a nitroalkene fatty acid and medium containing an anti-neoplastic agent into a mixing junction upstream of the chambers. Inline imaging tracks spheroid growth, and outlet samples support liquid chromatography and mass spectrometry measurements of drug recovery.

Automated or data-driven variant

Automated scoring of RAD51 focus formation

A liquid handler dispenses a concentration matrix of a thiolated nitro fatty acid and carboplatin into a multiwell plate containing tumor cells. An automated microscope acquires images of a nuclear stain, a DNA synthesis marker, and RAD51 immunofluorescence. Image analysis software segments nuclei, counts RAD51 foci in DNA synthesis marker-positive cells, and reports the fraction of those cells above a preset focus-count threshold for each concentration pair.

Cite aspatent.fyi, US 2026/0355140 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355140/, SHA-256 a79ffd593c65965b996bf25f1705e1c2a58d806a035d35cd27ee30bb743e63c2
First published
Permanent addresshttps://patent.fyi/US20260355140/
Content fingerprint (SHA-256)a79ffd593c65965b996bf25f1705e1c2a58d806a035d35cd27ee30bb743e63c2
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi